Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
Aventis is in the early stages of a plan to consolidate marketing-communications duties for its worldwide brands, the company confirmed last week. The estimated $300 million global advertiser begins the process with oncology drugs Taxotere and Genasense. Companies affected are within Havas, IPG, WPP and Omnicom. Havas’ Euro RSCG has Lantus; IPG’s McCann-Erickson handles Allegra. Neither is immediately affected.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in